Physician profile
Steven Blumlein
NPI 1568473361
$882.04
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $674 · 2020: $185 · 2021: $22.55.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $157.22 | 2019-2020 | |
| Amgen INC. | $99.94 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $96.41 | 2019 | |
| Astellas Pharma US INC | $92.67 | 2019 | |
| Novartis Pharmaceuticals Corporation | $78.42 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $75.71 | 2019-2020 | |
| Boston Scientific Corporation | $67.02 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $43.11 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $38.51 | 2019 | |
| Abiomed | $27.27 | 2020 | |
| Amarin Pharma, INC. | $23.79 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $22.55 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $21.96 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.97 | 2019 | |
| Chiesi USA, INC. | $16.49 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Blumlein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.